Skip to main content
. 2018 Aug 15;5(3):91. doi: 10.3390/medicines5030091

Table 1.

Summary of clinical evidence of dronabinol, nabilone, and nabiximols.

Dronabinol (Synthetic∆9-THC) Nabilone (Synthetic Analogue of ∆9-THC) Nabiximols (∆9-THC: Cannabidiol~1:1 (w/w))
Structure(s) graphic file with name medicines-05-00091-i001.jpg graphic file with name medicines-05-00091-i002.jpg graphic file with name medicines-05-00091-i003.jpg
Formulation Soft gelatin capsules (2.5, 5, 10 mg) Capsules (0.25, 0.5, 1 mg) Oro-mucosal spray (27 mg of ∆9-THC and 25 mg of cannabidiol/1.0 mL)
Disability and disease progression No evident changes No studies No evident changes
Pain Positive effects Positive effects Mixed findings (mostly positive effects)
Spasticity Mixed findings Positive effects Mixed findings (mostly positive effects)
Bladder function Mixed findings Positive effects Mixed findings
Ataxia and tremor No evident changes No studies No evident changes
Sleep Mixed findings (mostly positive effects) No studies Positive effects
Quality of life Mixed findings Mixed findings (moslty positive effects) Mixed findings
Adverse effects Mild to moderate. Principally dizziness, euphoria, dry mouth, fatigue and drowsiness. Moderate sedation, dizziness and moderate weakness in the legs. Mild to moderate. Principally drowsiness, dizziness, headache, fatigue, impaired balance and disturbance in attention.
Number of studies 10 3 11
Number of reviews 11 5 12
Studies (references) [45,46,47,48,49,50,51,52,53,54] [55,56,57] [58,59,60,61,62,63,64,65,66,67,68]
Reviews (references) [33,69,70,71,72,73,74,75,76,77,78] [69,70,72,73,78] [69,70,72,73,74,75,76,77,78,79,80,81]